Trevi Therapeutics (TRVI) Research & Development (2018 - 2025)

Trevi Therapeutics' Research & Development history runs 8 years deep, the most recent figure standing at $6.2 million for Q4 2025.

• On a quarterly basis, Research & Development fell 33.61% year-over-year to $6.2 million in Q4 2025; TTM through Dec 2025 was $35.0 million, a 11.13% decrease from a year earlier, with the FY2025 full-year figure at $33.5 million, down 14.98% from the prior year.
• Research & Development retreated to $6.2 million in Q4 2025 per TRVI's latest filing, from $10.1 million in the prior quarter.
• Across five years, Research & Development topped out at $11.2 million in Q3 2024 and bottomed at $4.3 million in Q4 2022.
• The 5-year median for Research & Development is $6.2 million (2025), against an average of $6.9 million.
• Across the five-year window, Research & Development surged 77.51% in 2024 and sank 33.61% in 2025, its largest moves.
• Year by year, Research & Development stood at $6.2 million in 2021, then slumped by 30.13% to $4.3 million in 2022, then soared by 50.98% to $6.5 million in 2023, then soared by 43.11% to $9.3 million in 2024, then plunged by 33.61% to $6.2 million in 2025.
• Per Business Quant, the three latest TRVI Research & Development figures stand at $6.2 million (Q4 2025), $10.1 million (Q3 2025), and $9.4 million (Q2 2025).